{"id":1522,"date":"2016-11-09T12:29:51","date_gmt":"2016-11-09T12:29:51","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1522"},"modified":"2021-07-24T12:56:34","modified_gmt":"2021-07-24T07:26:34","slug":"the-business-cocktail-5","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5","title":{"rendered":"Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f27137db9d5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f27137db9d5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5\/#Cancer_Research_UK_and_Cancer_Research_Technology_to_collaborate_with_TYG_Oncology\" >Cancer Research UK and Cancer Research Technology to collaborate with TYG Oncology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5\/#GE_Healthcare_and_Valneva_collaboration_results_in_cell_culture_medium_for_vaccine_production\" >GE Healthcare and Valneva collaboration results in cell culture medium for vaccine production<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5\/#UPS_to_Acquire_Marken\" >UPS to Acquire Marken<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5\/#Asymchem_Laboratories_Xbrane_Biopharma_Biohaven_Pharmaceutical_Holding_Company\" >Asymchem Laboratories, Xbrane Biopharma, Biohaven Pharmaceutical Holding Company<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Cancer_Research_UK_and_Cancer_Research_Technology_to_collaborate_with_TYG_Oncology\"><\/span>Cancer Research UK and Cancer Research Technology to collaborate with TYG Oncology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Cancer Research UK and Cancer Research Technology (CRT), the charity\u2019s commercial arm, have signed an agreement with TYG oncology (TYG) to take its TYG100, a new antigen-specific, active checkpoint control cancer vaccine, into clinical trials involving cancer patients with advanced solid tumours.TYG100 is a new treatment using a patient\u2019s own immune system to target hormones that encourage the growth and spread of solid tumours. This vaccine works by triggering the production of antibodies that particularly target two members of the gastrin hormone family, which fuel tumour growth.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"GE_Healthcare_and_Valneva_collaboration_results_in_cell_culture_medium_for_vaccine_production\"><\/span>GE Healthcare and Valneva collaboration results in cell culture medium for vaccine production<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">GE Healthcare\u2019s Life Sciences business and integrated vaccine biotech company, Valneva SE, has successfully collaborated to optimize virus productivity in Valneva\u2019s EB66 cell-line, a proprietary technology for the production of a wide variety of vaccines, including human and animal health. Viral production in EB66 cells includes secreted viruses, such as measles, alphaviruses, influenza A and B strains, and intracellular viruses, such as the modified vaccinia Ankara (MVA) virus. This collaboration has led to the creation of a commercial cell culture medium, HyClone CDM4Avian, developed to address the challenges of media variability.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"UPS_to_Acquire_Marken\"><\/span>UPS to Acquire Marken<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">UPS has entered into a definitive agreement to acquire Marken, a global provider of supply chain services to the life sciences industry. The transaction, subject to customary closing conditions, is expected to close by December 31. Financial details and terms were not disclosed. Marken operates a global network of clinical supply chain services to meet increasingly complex regulatory compliance demands for clients. UPS has been expanding its healthcare logistics services portfolio through several recent acquisitions.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Asymchem_Laboratories_Xbrane_Biopharma_Biohaven_Pharmaceutical_Holding_Company\"><\/span>Asymchem Laboratories, Xbrane Biopharma, Biohaven Pharmaceutical Holding Company<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Chinese-based contract manufacturing company\u00a0Asymchem Laboratories\u00a0has announced the issue of shares of its common stock in an initial public offering (IPO). The financial details of the IPO are yet to be disclosed. An exclusive, non-binding distribution agreement has been signed by Swedish biopharma company,\u00a0Xbrane Biopharma, with a Chinese pharmaceutical company to sell and market the former\u2019s product Spherotide in China. The drug is scheduled to be launched in 2021 and is estimated to have the potential to generate $38.8min annual revenue.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer Research UK and Cancer Research Technology to collaborate with TYG Oncology Cancer Research UK and Cancer Research Technology (CRT), the charity\u2019s commercial arm, have signed an agreement with TYG oncology (TYG) to take its TYG100, a new antigen-specific, active checkpoint control cancer vaccine, into clinical trials involving cancer patients with advanced solid tumours.TYG100 is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17399,17405,1842,17111,17404,17401,17403,17402,17400],"industry":[17225],"therapeutic_areas":[17227,17228],"class_list":["post-1522","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-asymchem-laboratories","tag-cancer-research-technology","tag-cancer-research-uk","tag-ge-healthcare","tag-marken","tag-tyg-oncology","tag-ups","tag-valneva","tag-xbrane-biopharma","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration<\/title>\n<meta name=\"description\" content=\"Cancer Research UK and Cancer Research Technology (CRT), the charity\u2019s commercial arm, have signed an agreement with TYG oncology (TYG)...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration\" \/>\n<meta property=\"og:description\" content=\"Cancer Research UK and Cancer Research Technology (CRT), the charity\u2019s commercial arm, have signed an agreement with TYG oncology (TYG)...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-09T12:29:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration","description":"Cancer Research UK and Cancer Research Technology (CRT), the charity\u2019s commercial arm, have signed an agreement with TYG oncology (TYG)...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5","og_locale":"en_US","og_type":"article","og_title":"Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration","og_description":"Cancer Research UK and Cancer Research Technology (CRT), the charity\u2019s commercial arm, have signed an agreement with TYG oncology (TYG)...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-11-09T12:29:51+00:00","article_modified_time":"2021-07-24T07:26:34+00:00","og_image":[{"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","width":1,"height":1,"type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5","name":"Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","datePublished":"2016-11-09T12:29:51+00:00","dateModified":"2021-07-24T07:26:34+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Cancer Research UK and Cancer Research Technology (CRT), the charity\u2019s commercial arm, have signed an agreement with TYG oncology (TYG)...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-5#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","caption":"Blue globes from drug capsule"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Asymchem Laboratories<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer Research Technology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer Research UK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GE Healthcare<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Marken<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TYG Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">UPS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Valneva<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Xbrane Biopharma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Asymchem Laboratories<\/span>","<span class=\"advgb-post-tax-term\">Cancer Research Technology<\/span>","<span class=\"advgb-post-tax-term\">Cancer Research UK<\/span>","<span class=\"advgb-post-tax-term\">GE Healthcare<\/span>","<span class=\"advgb-post-tax-term\">Marken<\/span>","<span class=\"advgb-post-tax-term\">TYG Oncology<\/span>","<span class=\"advgb-post-tax-term\">UPS<\/span>","<span class=\"advgb-post-tax-term\">Valneva<\/span>","<span class=\"advgb-post-tax-term\">Xbrane Biopharma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 9, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 9, 2016 12:29 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"Blue globes from drug capsule","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1522"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1522\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1200"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1522"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1522"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}